Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
|
31688618 |
2020 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
This is in line with previous reports on rare RUNX1 fusions in AML and emphasizes the clinical importance of their detection.
|
31756777 |
2020 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells.
|
31524877 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this study, we detected RUNX1-ETO and c-KIT gene expression in AML-M2 patients and verified the overexpression of c-KIT in t(8;21) AML patients.
|
30637949 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Aberrant CD79a and/or PAX5 expression can be found in AML cases with RUNX1 mutations even without the translocation t(8; 21).
|
30396184 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that the maintenance of t(8;21) AML is dependent on RUNX1-ETO expression.
|
31533028 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
The fusion gene AML1-ETO initially dysregulates various cell cycle molecules in t(8;21) acute myeloid leukemia.
|
31207577 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
AML with mutated <i>NPM1</i> and AML with myelodysplasia-related changes comprised the oldest patients, whereas AML with <i>RUNX1-RUNX1T1</i> included the youngest patients.
|
30623623 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Based on these 293 genes, the cyclooxygenase (COX), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways were predicted to be specifically activated in AMLs with <i>RUNX1-RUNX1T1</i> fusion.
|
30959925 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Interestingly, in comparison with AML1-ETO binding in acute myeloid leukemias (AMLs), we found significantly distinct genomic distribution and differential expression for RUNX1mut of genes such as <i>TCF4</i>, <i>MEIS1</i>, and <i>HMGA2</i> that may potentially contribute to the underlying difference in clinical outcomes between RUNX1mut and AML1-ETO patients.
|
30709863 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report.
|
30921216 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
RUNX1 is a key transcription factor in hematopoiesis and its disruption is one of the most common aberrations in acute myeloid leukemia.
|
30792202 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic fusion protein RUNX1-ETO is the product of the t(8;21) translocation, responsible for the most common cytogenetic subtype of acute myeloid leukemia.
|
30654457 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The t(7;21)(p22;q22) resulting in RUNX1-USP42 fusion, is a rare but recurrent cytogenetic abnormality associated with acute myeloid leukemia (AML) and myelodysplastic syndromes.
|
30706625 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
|
31247675 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
We describe here a case of AML with apparent amplification of RUNX1 by cytogenetics and FISH.
|
31425924 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The demonstration of RUNX1 mutation in both non-LCH and AML bone marrow specimens at differing time points is suggestive of a biologic association of both distinct disease entities.
|
30989185 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we show that gene expression profiling of RUNX1 knock-down or mutated MK provides a suitable approach to identify novel RUNX1 targets, among which downregulation of <i>TREML1</i> and <i>ITGA2</i> clearly contribute to the platelet phenotype of familial platelet disorder with predisposition to AML.
|
30545930 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
RUNX1-ETO is found in 10-15% of acute myeloid leukemia and interferes with the expression of genes that are essential for myeloid differentiation.
|
31826021 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recent studies identified a recurrent mutational hotspot, R222G, in DHX15 in ~ 6% of acute myeloid leukemia (AML) patients that carry the fusion protein RUNX1-RUNX1T1 produced by t (8;21) (q22;q22).
|
31691804 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
GATA2 and RUNX1 deficiency is not associated with host susceptibility to DNA damage, and therefore, conventional treatment strategies for MDS and AML can be used.
|
31808891 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
|
31638252 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Moreover, treatment with BET protein inhibitor or degrader (BET-proteolysis targeting chimera) repressed RUNX1 and its targets, inducing apoptosis and improving survival of mice engrafted with AML expressing mtRUNX1.
|
31023702 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The MM-VCEP began optimizing ACMG/AMP rules for RUNX1 because many germline variants have been described in patients with familial platelet disorder with a predisposition to acute myeloid leukemia, characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies.
|
31648317 |
2019 |
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
CTD_human |
Subtype-specific regulatory network rewiring in acute myeloid leukemia.
|
30420649 |
2019 |